TRANS-
FORMATION
Unlocked
At Elixir we believe that only by harnessing the power of transformation can there be real-world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.
We are a company developing disruptive platforms to treat coronary and peripheral artery disease.
TRANSFORMATION.
TRANS-
FORMA-
TION.
Unlocked.
At Elixir we believe that only by harnessing the power of transformation can there be real world impact. We are re-imagining how radical medical technologies will breathe new life into vascular interventions, reshaping it for decades to come.
We tackle big problems in vascular medicine.
We use transformation as a solution to improve health and quality of life for patients. By disrupting the status quo, we are going where others have given up.
CVDs are leading cause of death
244.1 million
About 6 million
patients undergo PCI (Percutaneous Coronary Intervention) every year
$407.3 billion
in direct and indirect cost in the United States3
805,000 annual heart attacks in US
20% of patients experience an adverse event
within 5 years after PCI procedure4
References
- https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
- https://professional.heart.org/
-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-GIobal-Burden-of-Disease.pdf - https://www.ahajournals.org/doi/epub/
10.1161/CIR.0000000000001123 - https://www.ahajournals.org/doi/full/
10.1161/CIRCINTERVENTIONS.114.002230
- https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1
- https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-GIobal-Burden-of-Disease.pdf
- https://www.ahajournals.org/doi/epub/10.1161/CIR.0000000000001123
- https://www.ahajournals.org/doi/full/10.1161/CIRCINTERVENTIONS.114.002230
PMN 2135 Rev A